Home LiteratureArticle Details
PMID: 10100307 Published · ppublish English Journal Article

Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption--theoretical approach.

Pharmaceutical research ·Vol. 16 ·No. 2 ·1999-02-00 ·Pages 225-31

Ito K, Kusuhara H, Sugiyama Y

Abstract

To evaluate the effects of gut metabolism and efflux on drug absorption by simulation studies using a pharmacokinetic model involving diffusion in epithelial cells. A pharmacokinetic model for drug absorption was constructed including metabolism by CYP3A4 inside the epithelial cells, P-gp-mediated efflux into the lumen, intracellular diffusion from the luminal side to the basal side, and subsequent permeation through the basal membrane. Partial differential equations were solved to yield an equation for the fraction absorbed from gut to the blood. Effects of inhibition of CYP3A4 and/or P-gp on the fraction absorbed were simulated for a hypothetical substrate for both CYP3A4 and P-gp. The fraction absorbed after oral administration was shown to increase following inhibition of P-gp. This increase was more marked when the efflux clearance of the drug was greater than the sum of the metabolic and absorption clearances and when the intracellular diffusion constant was small. Furthermore, it was demonstrated that the fraction absorbed was synergistically elevated by simultaneous inhibition of both CYP3A4 and P-gp. The analysis using our present diffusion model is expected to allow the prediction of in vivo intestinal drug absorption and related drug interactions from in vitro studies using human intestinal microsomes, gut epithelial cells, CYP3A4-expressed Caco-2 cells, etc.

MeSH Terms
ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism Absorption Computer Simulation Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme System/metabolism Epithelial Cells/metabolism Humans Intestines/enzymology Mixed Function Oxygenases/metabolism Models, Biological Pharmaceutical Preparations/metabolism Pharmacokinetics
Chemicals
ATP Binding Cassette Transporter, Subfamily B, Member 1 Pharmaceutical Preparations Cytochrome P-450 Enzyme System Mixed Function Oxygenases CYP3A protein, human Cytochrome P-450 CYP3A CYP3A4 protein, human
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Ito K
School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
Kusuhara H
Sugiyama Y
References (29)
29 references, click to expand
  1. Physiological measurements of luminal stirring in the dog and human small bowel.
    J Clin Invest. 1990 Nov;86(5):1540-7 PMID: 2243130
  2. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.
    Pharmacol Rev. 1998 Sep;50(3):387-412 PMID: 9755288
  3. Construction of a physiologically based pharmacokinetic model to describe the hepatobiliary excretion process of ligands: quantitative estimation of intracellular diffusion.
    Biol Pharm Bull. 1993 Mar;16(3):273-9 PMID: 8364472
  4. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.
    Biochem Biophys Res Commun. 1991 Mar 29;175(3):880-5 PMID: 1673839
  5. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes.
    J Clin Invest. 1992 Nov;90(5):1871-8 PMID: 1430211
  6. Cyclosporin-erythromycin interaction in renal transplant patients.
    Br J Clin Pharmacol. 1989 Apr;27(4):475-81 PMID: 2655690
  7. Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine.
    Pharm Res. 1995 Sep;12(9):1304-10 PMID: 8570526
  8. A quantitative study of fluorescein isothiocyanate-dextran transport in the microcirculation of the isolated perfused rat liver.
    Hepatology. 1989 Jan;9(1):75-82 PMID: 2461894
  9. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
    Clin Pharmacol Ther. 1997 Sep;62(3):248-60 PMID: 9333100
  10. Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3.
    Mol Pharmacol. 1997 May;51(5):741-54 PMID: 9145912
  11. Development of Caco-2 cells expressing high levels of cDNA-derived cytochrome P4503A4.
    Pharm Res. 1996 Nov;13(11):1635-41 PMID: 8956327
  12. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics.
    Biopharm Drug Dispos. 1996 May;17(4):273-310 PMID: 8845471
  13. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.
    Mol Carcinog. 1995 Jul;13(3):129-34 PMID: 7619215
  14. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.
    Pharmacol Ther. 1997;73(2):147-71 PMID: 9131722
  15. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine.
    Clin Pharmacol Ther. 1995 Jul;58(1):15-9 PMID: 7628178
  16. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport.
    Annu Rev Pharmacol Toxicol. 1998;38:461-99 PMID: 9597163
  17. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.
    Clin Pharmacol Ther. 1996 May;59(5):491-502 PMID: 8646820
  18. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues.
    J Pharmacol Exp Ther. 1990 Apr;253(1):387-94 PMID: 2329521
  19. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine.
    Clin Pharmacol Ther. 1995 Nov;58(5):492-7 PMID: 7586942
  20. How crowded is the cytoplasm?
    Cell. 1982 Sep;30(2):345-7 PMID: 6754085
  21. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier.
    J Pharm Pharmacol. 1996 Oct;48(10):1083-9 PMID: 8953513
  22. Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor.
    Drug Metab Dispos. 1998 Apr;26(4):360-6 PMID: 9531525
  23. First-pass metabolism of cyclosporin by the gut.
    Lancet. 1991 Dec 14;338(8781):1488-90 PMID: 1683920
  24. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
    J Pharmacol Exp Ther. 1997 Dec;283(3):1552-62 PMID: 9400033
  25. Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption.
    Pharm Res. 1997 Apr;14(4):486-91 PMID: 9144736
  26. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction.
    Clin Pharmacol Ther. 1992 Nov;52(5):453-7 PMID: 1424418
  27. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.
    J Toxicol Sci. 1996 Dec;21(5):309-16 PMID: 9035043
  28. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.
    Mol Pharmacol. 1996 Feb;49(2):311-8 PMID: 8632764
  29. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A.
    Biochem Pharmacol. 1997 Apr 25;53(8):1187-95 PMID: 9175724
Article Info
Journal
Pharmaceutical research
Abbr.
Pharm Res
ISSN
0724-8741
Published
1999-02-00
Pages
225-31
Language
English
Region
United States
NLM ID
8406521
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com